33 Business Park Drive #6, Branford, CT 06405
Evotec is a drug discovery alliance and development partnership company focused on rapidly pro-gressing innovative product approaches with leading pharmaceutical and biotechnology compa-nies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,000 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas in-cluding neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncol-ogy, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
The overall objective of Evotec is to become the global leader in high-quality drug discovery and development solutions. The execution of this strategy focuses on first-class innovation generated in partnerships with Pharma, biotech companies and academia. In addition, the aim is to scale the business, develop optimal cost structures and achieve maximal operational efficiency.
From January 2014 onwards, the Company has been operating and managing its business activities under the two segments EVT Execute and EVT Innovate:
Evotec has evolved into one of the global leaders in providing complete drug discovery solutions on a stand-alone basis or through holistic, fully integrated drug discovery solutions.
EVT Innovate includes the advanced drug candidates and the early-stage internal discovery programs, which focus on first-in-class and best-in-class projects based on innovative biology.
These so called “Cure X” or “Target X” initiatives largely follow indication areas that are firmly established at Evotec: metabolic and inflammatory disease, neurology, oncology, immuno-oncology and pain as well as infectious diseases. Projects are selected to match Evotec’s expertise and technology and positioned for partnering with Pharma customers, usually at pre-clinical stages. Ensuing partnerships usually involve upfront and research payments as well as milestones and product royalties.
United States HQ: 303B College Road East, Princeton, NJ 08540
Global HQ: Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany